Vårdprogram för Urotelial urinblåsecancer 2000 - Medac

01-09-27
Referenslista
1. Cancer i Sydöstra Sverige 1997. Onkologiskt Centrum för Sydöstra sjukvårdsregionen,
Linköping 1998.
2. Cancer incidence in Sweden 1997. National Board of Health and Welfare, centre for
epidemiology 1999.
3. Nationellt kvalitetsregister för blåscancer- diagnosår 1998. Regionala tumörregistret,
universitetsjukhuset i Lund.
4. Urotelial blåscancer i sydöstrasjukvårdsregionen 1992-1997. Onkologiskt Centrum för
Sydöstra sjukvårdsregionen, Linköping 1999.
5. Sobin LH, Wittekind C (eds). TNM classification of malignant tumors. Fifth edition. John
Wiley and sons Inc., 1997.
6. Hellsten S, Malmström P-U, Månsson W, Alexandersson P. Cancer i urinblåsan - State of
the art. Socialstyrelsen1998, ISBN 91-7201-105-X
7. Beisland HO, Seland P. A prospective randomized study on Neodynium-YAG laser
irradiation of urinary bladder tumours. Scand J Urol 1986;20:209-212.
8. Oosterlinck W, Jakse G, Malmström P-U,Stöckle M, Sternberg C, Neal D, Calais da Silva
F. European Association of Urology, Guidelines on bladder cancer.
9. LutzeyerW, Ruben H,Dahm H. Prognostic parameters in superficial bladder cancer. An
analysis of 315 cases. J Urol 1982; 127: 250-2.
10. Jenkins BJ, Nauth-Misisr RR, Martin JE, Fowler CG, Hope-Stone HF, Blandy JP. The
fate of theG3pT1 bladder cancer. Br J Urol 1989; 64: 608-10.
11. Herr HW. Tumour progression and survival in patients with T1G3 bladder tumours: 15year
outcome. Br J Urol 1997;80: 762-765.
12. Herr HW. Tumor progression and survival of patients with high grade, noninvasive(TaG3)
papillary bladder tumors: 15-year outcome. J Urol 2000;163: 60-62
13. Herr HW. The value of a second transurethral resection in evaluating patients with bladder
tumors. J Urol 1999; 162; 74-76, 2000.
14. Sobin LH, Wittekind Ch.. TNM classification of malignant tumours. Fifth edition, New
York: Wiley-Liss, 1997.
15. Holmäng S, Hedelin H, Anderström C, Holmberg E, Johansson SL. Long-term follow-up
of a bladder cancer cohort: routine follow-up urography is not necessary. J Urol 1998;
160:45-48.
16. Lebret T, Bohin D, Kassardjian Z, Herve J-M, Molinie V, Barre P, Lugagne P-M, Botto
H. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with
low dose Bacillus Calmette-Guèrin instillations. J Urol 2000; 163: 63-67
17. Parmar MKB, Freedman LS, Hargreave TB, Tolley DA. Prognostic factors and follow up
policies in the treatment of superficial bladder cancer: report from the British Medical
Research Council subgroup on superficial bladder cancer(urological cancer working
party).J Urol 1989; 142: 284-288.
18. Oosterlinck W, Kurth KHn, Schröder F, Bultinck J, Hammond B, Sylvester R and the
members of the European Organization for Research and Treatment of Cancer
Genitourinary Group. A prospective European Organization for Research and Treatment
of Cancer genitourinary Group randomized trial comparing transurethral resection
followed by a single intravesical instillation of Epirubicin or water in single stage Ta, T1
papillary carcinoma of the bladder. J Urol 1993;149: 749-752.
19. Malmström PU, Wijkström H, Lundholm C et al 5-year follow-up of a randomized
prospective study comparing mitomycin C and Bacillus Calmette-Guérin in patients with
superficial bladder carcinoma. J Urol 1999; 161: 1124-1127.
20. Lamm DL, Crawford ED, Blumenstein B et al Maintenance BCG immunotherapy of
superficial bladder cancer: a randomized prospective Southwest Oncology Group study. J
urol 1992; 147:274A(Abstract 242)
19